Replies to post #291248 on Amarin Corp Plc (AMRN)

[Cardiologymd]

And no outcome study. Useless.

[anfla]

Except they couldn’t sell it for many years until they run a Reduce It trial for $300m. No guarantee they produce similar or the same results. If you have worse results, it could tarnish a Reduce It. In 5-7 years when the trial is done, Vascepa will be mature and own the market. It’ll be hard to transition people. If Vascepa is cheaper, it won’t matter. And they already own an ethyl ester produce from Japan. So stronger reasons not to do it.